Roosevelt Investment Group Inc. Sells 133 Shares of Eli Lilly And Co (NYSE:LLY)

Roosevelt Investment Group Inc. trimmed its position in shares of Eli Lilly And Co (NYSE:LLY) by 4.8% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,615 shares of the company’s stock after selling 133 shares during the period. Roosevelt Investment Group Inc.’s holdings in Eli Lilly And Co were worth $339,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in LLY. Athena Capital Advisors LLC bought a new position in Eli Lilly And Co in the fourth quarter valued at approximately $26,000. Wakefield Asset Management LLLP bought a new position in Eli Lilly And Co in the fourth quarter valued at approximately $27,000. Larson Financial Group LLC acquired a new stake in Eli Lilly And Co in the fourth quarter worth $29,000. Trust Department MB Financial Bank N A raised its holdings in Eli Lilly And Co by 54.7% in the first quarter. Trust Department MB Financial Bank N A now owns 232 shares of the company’s stock worth $30,000 after purchasing an additional 82 shares during the period. Finally, Acima Private Wealth LLC acquired a new stake in Eli Lilly And Co in the fourth quarter worth $33,000. Institutional investors own 79.37% of the company’s stock.

LLY stock traded up $1.95 during trading on Monday, reaching $112.74. 3,235,604 shares of the company were exchanged, compared to its average volume of 10,756,533. Eli Lilly And Co has a twelve month low of $84.71 and a twelve month high of $132.13. The company has a debt-to-equity ratio of 5.50, a current ratio of 1.12 and a quick ratio of 0.85. The company has a market capitalization of $108.04 billion, a P/E ratio of 20.31, a price-to-earnings-growth ratio of 1.96 and a beta of 0.20. The business’s 50-day moving average is $115.21.

Eli Lilly And Co (NYSE:LLY) last posted its earnings results on Tuesday, April 30th. The company reported $1.33 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.32 by $0.01. Eli Lilly And Co had a net margin of 26.13% and a return on equity of 56.62%. The firm had revenue of $5.09 billion for the quarter, compared to analyst estimates of $5.12 billion. During the same period in the previous year, the firm posted $1.31 EPS. The company’s revenue for the quarter was up 2.6% compared to the same quarter last year. As a group, research analysts forecast that Eli Lilly And Co will post 5.66 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Thursday, August 15th will be issued a dividend of $0.645 per share. This represents a $2.58 dividend on an annualized basis and a yield of 2.29%. The ex-dividend date of this dividend is Wednesday, August 14th. Eli Lilly And Co’s payout ratio is 46.49%.

In related news, CFO Joshua L. Smiley bought 426 shares of the business’s stock in a transaction that occurred on Wednesday, June 5th. The shares were acquired at an average cost of $118.03 per share, with a total value of $50,280.78. Following the completion of the purchase, the chief financial officer now directly owns 30,410 shares in the company, valued at $3,589,292.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Michael J. Harrington sold 16,000 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $116.72, for a total transaction of $1,867,520.00. Following the transaction, the vice president now owns 110,300 shares in the company, valued at approximately $12,874,216. The disclosure for this sale can be found here. Insiders have sold a total of 40,112 shares of company stock worth $4,820,705 over the last three months. Insiders own 0.11% of the company’s stock.

Several equities research analysts have weighed in on the stock. Goldman Sachs Group assumed coverage on shares of Eli Lilly And Co in a report on Tuesday, May 28th. They issued a “buy” rating and a $135.00 target price on the stock. Cantor Fitzgerald reiterated a “buy” rating and issued a $143.00 target price on shares of Eli Lilly And Co in a report on Tuesday, April 30th. Guggenheim lowered shares of Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $125.84 target price on the stock. in a report on Thursday, April 11th. Barclays restated a “buy” rating and set a $140.00 price objective on shares of Eli Lilly And Co in a report on Sunday, April 14th. Finally, Credit Suisse Group set a $121.00 target price on shares of Eli Lilly And Co and gave the stock a “hold” rating in a report on Friday, March 22nd. Ten research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Eli Lilly And Co has a consensus rating of “Buy” and a consensus target price of $119.99.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: What does EPS mean?

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.